Does Rallies show Form 4 insider transactions for KPTI?

Yes. Rallies tracks KPTI insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is KPTI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for KPTI. It does not provide personalized investment advice.

KPTI (Karyopharm Therapeutics Inc.) Stock Analysis - Insider Trades

Karyopharm Therapeutics Inc. (KPTI) is a publicly traded Healthcare sector company. As of May 21, 2026, KPTI trades at $7.84 with a market cap of $161.81M and a P/E ratio of -0.48. KPTI moved +6.69% today. Year to date, KPTI is +7.84%; over the trailing twelve months it is +54.80%. Its 52-week range spans $3.51 to $16.95. Analyst consensus is strong buy with an average price target of $15.83. Rallies surfaces KPTI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading KPTI stock inside the company?

Recent KPTI insider activity includes Poulton Stuart sold 403, Rangwala Reshma sold 408, Cheng Sohanya Roshan sold 324, Abate Kristin sold 53, and Paulson Richard A. sold 2.20K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

KPTI Key Metrics

Key financial metrics for KPTI
Metric	Value
Price	$7.84
Market Cap	$161.81M
P/E Ratio	-0.48
EPS	$-16.16
Dividend Yield	0.00%
52-Week High	$16.95
52-Week Low	$3.51
Volume	122
Avg Volume	0
Revenue (TTM)	$151.12M
Net Income	$-194.97M
Gross Margin	0.00%

Recent KPTI Insider Trades

Poulton Stuart sold 403 (~$3.83K) on May 14, 2026.
Rangwala Reshma sold 408 (~$3.88K) on May 14, 2026.
Cheng Sohanya Roshan sold 324 (~$3.08K) on May 14, 2026.
Abate Kristin sold 53 (~$503.5) on May 14, 2026.
Paulson Richard A. sold 2.20K (~$20.93K) on May 14, 2026.

Latest KPTI News

Karyopharm Posts Q1 Revenue Growth, Cuts Loss to $22.4M, Completes EC042 Enrollment — May 15, 2026
Karyopharm Therapeutics Beats Q1 Estimates with $35.07M Revenue, -$1.02 EPS — May 14, 2026
Karyopharm Narrows Q4 Loss to $2.23 Per Share, Beats Revenue Forecasts — Feb 12, 2026

KPTI Analyst Consensus

7 analysts cover KPTI: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $15.83.

Common questions about KPTI

Who is trading KPTI stock inside the company?: Recent KPTI insider activity includes Poulton Stuart sold 403, Rangwala Reshma sold 408, Cheng Sohanya Roshan sold 324, Abate Kristin sold 53, and Paulson Richard A. sold 2.20K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for KPTI?: Yes. Rallies tracks KPTI insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is KPTI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for KPTI. It does not provide personalized investment advice.